Biobanking: Technologies and Global Markets
The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.
- An overview of the global markets for biobanking, the storage of biological samples for the future.
- Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
- Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
- Breakdowns of the biobanking market by product, disease category, and geographic region or country.
- New products approved by the FDA, and those products expected to be approved within the forecast period.
- Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
- Profiles of the manufacturers of leading products, and their specific product strategies are outlined.
This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report’s release.
Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report. The competitive market environment is evaluated with a unique emphasis on the effect of the new technologies and products on the prevailing patient care standard. Emerging companies and current leaders in the market are profiled and discussed in detail.
Market figures are founded on the revenue level of the manufacturers and forecast done in the 2016-dollar value. Forecast figures exclude inflation. Parameters like the introduction of new products, forecast sales for prevailing products, expanded indications for prevailing products and forecasted changes in the rates of diagnosis, prevalence and scripting for specific diseases are considered when assessing trends.
Forecasts featured in this report for the period between 2016 and 2021 are based on disease category, product and company. The study is organized for an overview of the biobanks market by geography, company and product. The projections are based on country or geographic region. For every disease sub-segment, the global market is evaluated and data provided.
Consumables that do not require prescription from a physician like over-the-counter (OTC) drugs are not covered in this report.
Sales figures are in U.S. dollars, with each reflecting change in revenue performance due to currency fluctuations. Variations in local currencies, however, are not accounted for by the revenue figures.
Unless pointed out, all data on market share in the report are on a global basis.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.
The global biobanking market was $141 billion in 2010 and is projected to increase by 30% between 2010 and 2015, at a compound annual growth rate (CAGR) of 5.4%.